Results 111 to 120 of about 312,671 (350)

Anti‐inflammatory and Gastroprotective Effects of the Chamaerops humilis L. (DOUM) Fruit Aqueous Extract in Experimental Models of Edema and Gastric Ulcer

open access: yesChemistry &Biodiversity, EarlyView.
ABSTRACT Chronic inflammation can lead to various diseases, including gastric ulcers, highlighting the need for effective therapeutic strategies. The traditional use of Chamaerops humilis in Moroccan folk medicine for treating gastrointestinal disorders underscores its potential as a valuable natural remedy.
Yasmina Jaouhari   +12 more
wiley   +1 more source

Uncovering anorexia nervosa in a biofeedback clinic for bowel dysfunction [PDF]

open access: yes, 2012
Biofeedback is a conservative treatment based on behavioural techniques, which can be used in the management of bowel dysfunction. This article reports the results of a retrospective review of the clinical notes of 87 female patients attending a ...
Chelvanayagam, Sonya   +3 more
core   +1 more source

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash   +1 more
wiley   +1 more source

Randomized Double-blind Controlled Trial: Benefits of Lactobacillus Reuteri in Chronic Functional Constipation Patients [PDF]

open access: yes, 2015
Background: Chronic functional constipation is a common problem that affects between 15-25% of the population and cause symptoms and disorders that creates discomfort, morbidity, and high costs for health care.
Agustinus, T. (Taolin)   +3 more
core   +2 more sources

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek   +9 more
wiley   +1 more source

A modern view of the problem of constipation

open access: yesЛечащий Врач
Background. PA new chronomedical approach to the classification of one of the most common syndromes in modern medicine, the constipation syndrome, is presented. According to Robert Hegglin "сonstipation is the absence of defecation for 24 hours".
Konstantin A. Shemerovskii   +2 more
doaj   +1 more source

Evaluation of Constipation Risk among Inpatients in Surgery and Internal Medicine Wards

open access: yesTurkish Journal of Colorectal Disease, 2019
Aim: This study was conducted to evaluate the risk of constipation among inpatients in the surgery and internal medicine wards. Method: This descriptive study included 251 inpatients being treated in the Ağrı State Hospital between April 2018 and June ...
Şenay Karadağ Arlı
doaj   +1 more source

Changes in neuromuscular structure and functions of human colon during ageing are region-dependent [PDF]

open access: yes, 2018
Objective: To determine if human colonic neuromuscular functions decline with increasing age.Design: Looking for non-specific changes in neuromuscular function, a standard burst of electrical field stimulation (EFS) was used to evoke neuronally mediated (
Ahmed, Shafi   +13 more
core   +2 more sources

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35.
Yingxue Chen   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy